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The first lesson gained from our studies of Hutchinson-Gilford 
progeria syndrome (HGPS) sounds simple enough: Approach 
any translational opportunity that may cross your path with an 
inquisitive mind. However, because it is nearly impossible to 
predict when, where, or how such opportunities might arise, the 
challenge is to remain open to the potential at all times and in 
all places.
For example, the seeds of our collaboration were sown 
about a decade ago at a decidedly nonscientific venue: a cock-
tail party in Washington, D.C. During the event, the genomic 
researcher among us (Collins) happened to strike up a conver-
sation with a young emergency room physician (Scott Berns)   
doing a White House Fellowship. The ER doctor mentioned 
that he and his physician-scientist wife (Gordon) had a young 
son with HGPS, which is a rare, genetic disease characterized 
by rapid, premature aging (Gordon et al., 2003). The molecular 
cause of HGPS was unknown at the time, making the search 
for potential treatments and cures all but impossible. Berns told 
Collins  that  the  couple  had  founded The  Progeria  Research 
Foundation to encourage scientists to work on this formidable 
challenge. After a few more conversations, the genomic re-
searcher was “hooked,” and agreed to help organize a workshop 
to help track down the genetic mutation responsible for HGPS. 
Pretty soon his laboratory joined in.
So, what does it take to hook basic researchers on trans-
lational challenges? There are a few elements that strike us as 
crucial, perhaps even essential, to motivating basic scientists to 
apply their work toward clinical problems. Among the foremost 
is human need. In the case of HGPS, the need was obvious: 
there was no treatment for the disease, and patients died from 
cardiovascular disease at around age 13. Another key motiva-
tor is intellectual challenge. Nature may pose much tougher   
research questions than we can dream up ourselves, as we have 
learned time and time again in our decade of studying HGPS.
We must also recognize the motivating force of techno-
logical innovation. Clinical problems once considered too dif-
ficult or time-consuming to be tackled by basic research can 
become amenable to solution thanks to the development of new 
tools and technologies. In the genomic sector, such innovation 
includes databases containing the reference sequence of the 
human genome, maps of human genetic variation, and ever-
expanding  catalogs  of  human  genotype/phenotype  correlations. 
Fueling this tsunami of genomic discovery are technologies that 
have dramatically cut the cost of DNA sequencing from $100 
million per genome in 2001 to less than $8,000 today.
Cell biology, too, has benefitted greatly from technologi-
cal advances over the past decade. These advances include the 
development of the spinning disk and other advanced confo-
cal microscopes that, along with higher speed cameras, make 
it possible to record 3D images in living cells over long periods 
of time (Gerlich and Ellenberg, 2003). Using the techniques of 
photobleaching and photoactivation, new fluorophores with a 
variety of excitation wavelengths have also provided additional 
tools to label and track how proteins behave in living cells 
(Lippincott-Schwartz et al., 2003; Miyawaki et al., 2003). In 
addition to better imaging tools, cell biologists now have access 
to many more wet-bench biochemical assays and kits for deter-
mining various cellular processes, including apoptosis, senes-
cence, protein phosphorylation, ATP production, and cell stress. 
These types of tools have been essential for dissecting out 
the molecular mechanisms underlying HGPS.
Cell  biologists  love  to  think  outside  the  box,  pursuing 
many surprising twists and unexpected turns in their quest 
to unravel the mysteries of how cells work. But can cell   
biologists think outside the bench? We are certain that 
they can, and clearly some already do. To encourage 
more cell biologists to venture into the realm of transla-
tional research on a regular basis, we would like to share 
a handful of the many lessons that we have learned in our 
effort to develop experimental treatments for Hutchinson- 
Gilford  progeria  syndrome  (HGPS),  an  endeavor  that 
many view as a “poster child” for how basic cell biology 
can be translated to the clinic.
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modified (Fig. 1), with the addition of a farnesyl group at the 
C terminus that seems to assist in “zip-coding” the protein to the 
inner surface of the nuclear membrane. The protein then needs   
to be released from this tether, which is accomplished by an   
enzyme called ZMPSTE24. The abnormal splice event that gives 
rise to progerin eliminates the ZMPSTE24 cleavage, so progerin 
remains permanently farnesylated. To explore the cell biological 
consequences, we forged a rewarding collaboration with Robert 
Goldman, noted for his lamin A work. His laboratory helped 
us to document quickly the consequences of LMNA mutations   
at the cellular level, including abnormal nuclear morphology, 
premature senescence, and loss of peripheral heterochromatin 
(Fig. 2, A, D, and E; Goldman et al., 2004). It also became clear 
that we needed more cell biology expertise within our own 
group, and, in 2005, the Collins laboratory recruited a postdoc 
(Cao) with a strong background in cell biology research. The 
move paid off, and subsequent work showed effects of LMNA 
mutations on mitosis, causing incomplete disassembly of nuclear 
envelope, chromosome missegregation, and binucleation (Fig. 2, 
B and C; Cao et al., 2007; Dechat et al., 2007).
Our pathway from bench to clinic has been illuminated 
by the brilliance of a diverse array of scientists, including seminal 
papers describing the genomic instability in HGPS (Liu et al., 
2005) and the mechanical changes in the lamina of HGPS cells 
(Dahl et al., 2006). Likewise, several groups have generated   
induced pluripotent stem (iPS) cells from HGPS patients, pro-
viding all of us in the field with a powerful new tool for studying 
the pathogenesis of HGPS and testing new therapeutic strate-
gies (Liu et al., 2011; Zhang et al., 2011; Progeria Research 
Foundation, 2012).
Clinical consequences: Time is of  
the essence
Like most biomedical researchers, cell biologists aspire to see 
their discoveries turned into better health outcomes as swiftly 
as possible. However, in our experience, the translational clock 
usually ticks faster when there is a clinician on the translational 
team who is acutely aware of how short the timeline is for 
many who suffer from lethal, progressive diseases, or when basic 
Get to the root of the problem
Our second lesson is often easier said than done: get to the root 
of the problem. When confronted with heartbreaking human 
need and urgent clinical challenges, it is tempting to race ahead 
to exploring therapeutic possibilities before gaining a firm, or 
even tentative, grasp on the molecular roots of a disease. But 
much time, money, and, ultimately, lives may be lost if a trans-
lational research team rushes into clinical trials without a basic 
understanding of the molecular mechanisms underlying the dis-
ease in question.
In the case of HGPS, we were fortunate that it only took us 
a couple of years to get the proverbial cart hooked up to the horse 
and heading in the right direction. In 2003, through a combination 
of hard work and serendipity, the Collins laboratory discovered 
that HGPS is caused by a C-to-T point mutation near the end of 
the lamin A (LMNA) gene (Eriksson et al., 2003). The point muta-
tion activated a splice donor in the middle of an exon, leading to 
the production of an abnormal protein, now called progerin, that 
is 50 amino acids shorter than normal (Fig. 1).
Since the gene discovery, understanding of HGPS has 
advanced at a rapid pace, fueled by basic research using both 
in vitro and animal models of disease. This understanding has 
opened many doors; some were expected, others unexpected, 
with  some  leading  to  exciting  translational  strategies  and   
others pointing us back to the basics of human biology. How 
we set about exploring what lay beyond these doors leads us 
to our third lesson.
Build upon previous knowledge
U.S. President Woodrow Wilson once remarked, “I not only 
use all the brains I have, but all that I can borrow.” In the case 
of HGPS, although the earliest iteration of our team was made 
up primarily of genomic researchers, molecular biologists, and 
clinical researchers, we soon realized the need to access the   
impressive body of knowledge offered to us by cell biology.
Once we discovered that the LMNA gene was the culprit 
in HGPS, nearly two decades of lamin A cell biology provided 
almost immediate insights about how this mutation might cause 
disease in a dominant fashion. Lamin A is posttranslationally 
Figure  1.  Posttranslational  processing  of 
lamin  A.  A  farnesyl  group  is  added  to  the 
C terminus of the lamin A protein by the en-
zyme farnesyltransferase, and, subsequently, 
the last three amino acids are cleaved by the 
endoprotease  ZMPSTE24.  ZMPSTE24  then   
removes the terminal 15 amino acids, a step 
that is blocked in HGPS because of the in-
ternal  deletion  of  the  cleavage  site  in  the 
progerin protein.11 Progeria: Translational insights • Gordon et al.
Our group developed a mouse model of HGPS by re-
engineering human LMNA to carry the HGPS mutation, and 
then inserting it into the mouse germline (Varga et al., 2006). Our 
mice lack the skin, hair, or bone abnormalities seen in humans 
with HGPS, but, like the human patients, exhibit progressive 
loss of vascular smooth muscle cells in the media of large arter-
ies. Tests of FTIs in this and other mouse models (Fong et al., 
2006; Capell et al., 2008) complemented other data in support 
of an initial clinical trial that administered an FTI, lonafarnib,   
to HGPS patients (Fig. 3). Other work provided an evidence-based 
rationale (Varela et al., 2008) for a second generation of clinical 
trials that combined FTIs with statins and bisphosphonates.
Nonclinicians embarking on translational research projects 
would also do well to acquaint themselves with another power-
ful time saver: studies of the natural history of the disease in 
humans. Well-conducted natural history studies can define the 
range of manifestations and progression of rare conditions, and 
also identify biomarkers and other correlates of clinical out-
comes that can be used to design an effective clinical trial. In the 
case of HGPS, such studies were limited, and so efforts to iden-
tify statistically reliable outcome measures (Gordon et al., 2007, 
scientists interact with patients and their families through meet-
ings organized by advocacy groups (Gordon et al., 2008).
While our discovery of the LMNA mutation and eluci-
dation of its mechanism of action raised a host of fascinating 
questions that could fuel years of basic research, we also knew 
that time was of the essence for children with HGPS and their 
families. Because HGPS is so rare, and many HGPS patients are 
in fragile health, there are very limited opportunities to conduct 
human trials of potential therapies. Consequently, we needed   
to select and use the scientific tools at our disposal in highly 
strategic ways if we were to move forward expeditiously.
Theory predicted that farnesyltransferase inhibitors (FTIs) 
would be of potential use in HGPS by reducing the amount of 
permanently farnesylated progerin, so that is where we began. 
Tests in cell culture by the Collins laboratory and others showed 
that FTIs can significantly ameliorate the nuclear-shape abnor-
malities seen in HGPS cells (Capell et al., 2005). However, 
cells could only take us so far in the preclinical space. We also 
needed a good animal model with the precise genetic mutation 
seen in humans or, even better, a number of genetically precise 
models created via multiple strategies.
Figure 2.  Defects in HGPS cells. (A) Abnormal nuclear morphology (nuclear blebbing). A nucleus of a passage 17 HGPS cell (HGADFN167) was stained 
in green with an anti–lamin A/C antibody. (B) Mitotic defects. Nuclear disassembly is incomplete at the onset of mitosis. Progerin (green signal) forms giant 
aggregates in mitotic cytoplasm. DNA is stained in blue. (C) Binucleation. A binucleated HGPS cell (HGADFN167) stained with an anti-progerin antibody 
is shown in green. (D) Premature senescence. Senescence-associated -galactosidase staining is shown for HGPS cells (HGADFN167) at passage 17.   
(E) Loss of peripheral heterochromatin and extensive nuclear disorganization of a passage 18 HGPS cell (HGADFN167). Source of cells: the Progeria 
Research Foundation Cell and Tissue Bank (Providence, RI). A, D, and E are courtesy of K. Cao. B and C are from Cao et al. (2007), copyright the National 
Academy of Sciences. Bars: (A–C and E) 5 µm; (D) 20 µm.JCB • VOLUME 1 • NUMBER 1 • 2012   12
These findings establish HGPS as a valid model system for   
future basic research into aging.
The example of HGPS should make it clear that translational 
science is not just a one-way street, with basic research discoveries 
flowing from the bench toward more applied research in the clinic. 
Rather, the translational process is a virtuous circle, in which basic 
science benefits clinical research and vice versa. In the span of a 
decade, HGPS has gone from being a rare and mostly ignored dis-
order to being “hot science” in both basic and clinical journals. If 
clinical researchers had not persuaded basic researchers to devote 
significant effort to solving the translational riddle posed by HGPS, 
the entire biology community might have missed out on a valuable 
window into development, senescence, and aging.
You can do it too!
Although this is still a work in progress, we think HGPS is a trans-
lational success story worth repeating, and we would like to en-
courage more cell biologists to give it a try. With more than 4,500 
human  conditions  now  having  their  molecular  causes  defined, 
many scientists working on basic research into particular genes, 
proteins, or pathways may have new opportunities to make these 
translational connections. For cell biologists who are considering 
heading down the translational pathway, we suggest checking out 
the Online Mendelian Inheritance in Man database (http://www 
.omim.org/) to see what disorders might now connect to their work. 
We also encourage cell biologists to reach out to clinicians and 
patient advocacy organizations to seek potential collaborations, as 
well as to welcome the occasions when they reach out.
It  is  true  that  serendipity  played  a  significant  role  for 
HGPS, and that does not always happen. But we do view our ex-
perience as a beacon of hope that shows what basic and clinical 
researchers can accomplish when they join together to tackle a 
translational challenge. The scientific opportunities have never 
been better. We look forward to seeing what cell biology can do 
in the next few years to help us light up more of these beacons 
for the millions of people awaiting treatments and cures.
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2011; Merideth et al., 2008; Gerhard-Herman et al., 2012) had 
to proceed simultaneously with the planning and implementa-
tion of treatment trials.
Our therapeutic efforts may soon extend to a third genera-
tion of HGPS clinical trials. Work in cell culture supports the 
possibility that an analogue of rapamycin, an FDA-approved 
immunosuppressant  drug  used  to  prevent  rejection  in  organ 
transplantation, may provide benefit if added to the current 
combination approach. The nuclear morphology analysis work 
that provided a quantitative assessment of treatment effective-
ness also highlights how cell biology can serve to guide, not 
just support, translational strategies (Cao et al., 2011a; Driscoll 
et al., 2012).
Readers will have noted that all of these therapeutic ideas 
have been based upon repurposing drugs originally developed 
for other purposes. But that is not the only option. Led by a bet-
ter understanding of the basic biology of HGPS, concurrent in-
vestigations on high throughput assay and drug development 
(Auld et al., 2009), gene therapy (Scaffidi and Misteli, 2005; 
Osorio et al., 2011), and stem cell treatment (Wenzel et al., 
2012) may all provide future opportunities for combating, and 
perhaps even curing, HGPS.
Translational research may yield  
basic insights
Although the primary goal of translational research is helping 
patients, basic researchers going after this goal may also find 
themselves rewarded with unexpected insights into fundamen-
tal biological processes. In our case, the translation-oriented 
discovery of the HGPS mutation paved the way for a series 
of cell biology studies that demonstrated that progerin is also 
made in normal cells. The splice site activated in HGPS to cre-
ate progerin is actually used at a low level in normal cells, and 
becomes more active as cell senescence approaches (Scaffidi 
and Misteli, 2006; McClintock et al., 2007; Olive et al., 2010). 
This splice site even may play a role in normal development, 
such as in closure of the ductus arteriosus (Bökenkamp et al., 
2011). Most recently, our work suggests that use of this splice 
site is somehow triggered by shortened telomeres, hastening the 
irreversible process of cellular senescence (Cao et al., 2011b). 
Figure 3.  Children with HGPS. Participants in a clinical trial of an FTI. Photographs courtesy of The Progeria Research Foundation.13 Progeria: Translational insights • Gordon et al.
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